ERK1/2 inhibitor U0126 can promote XBP1s' nuclear translocation in cardiomyocyte by restricting its phosphorylation and SUMOylation in vitro and in vivo, provides novel therapeutic avenue for DCM. Here, MAPK3 is linked to familial dilated cardiomyopathy.